Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Doravirine in Hepatic Insufficiency
NCT02089659Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity at 144 hours, Maximum Observed Plasma Concentration at 144 hours and 2 more. Started Mar 2014; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02089659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089659.